Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP4 | P15090 | 2/20 | 0.56 |
| ▸ | FABP5 | Q01469 | 2/20 | 0.56 |
| ▸ | MAOA | P21397 | 11/20 | 0.54 |
| ▸ | MAOB | P27338 | 11/20 | 0.54 |
| ▸ | ACHE | P22303 | 3/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.54 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.54 |
| ▸ | GRIN1 | Q05586 | 9/20 | 0.51 |
| ▸ | GRIN2A | Q12879 | 9/20 | 0.51 |
| ▸ | GRIN2B | Q13224 | 9/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6338101 | 0.84 | MAOA (0.69) | FABP4FABP5MAOAMAOBACHE | |
| SCHEMBL5658338 | 0.84 | MAOA (0.69) | FABP4FABP5MAOAMAOBACHE | |
| SCHEMBL10063551 | 0.84 | MAOA (0.69) | FABP4FABP5MAOAMAOBACHE | |
| SCHEMBL5181736 | 0.84 | MAOA (0.69) | FABP4FABP5MAOAMAOBACHE | |
| SCHEMBL4552481 | 0.82 | FABP4 (0.68) | FABP4FABP5MAOAMAOBACHE | |
| Boric Acid SCHEMBL28519644 | 0.81 | CNR2 (0.58) | FABP4FABP5MAOAMAOBACHE | |
| Boric Acid SCHEMBL27900573 | 0.81 | CNR2 (0.58) | FABP4FABP5MAOAMAOBACHE | |
| SCHEMBL2216141 | 0.81 | RORA (0.61) | — | |
| SCHEMBL24398894 | 0.79 | FABP4 (0.61) | FABP4FABP5MAOAMAOBACHE | |
| SCHEMBL30622271 | 0.79 | FABP4 (0.61) | FABP4FABP5MAOAMAOBACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080107918-A1 | METHOD FOR SYNTHESIZING ANTHRACENE DERIVATIVE AND ANTHRACENE DERIVATIVE, LIGHT EMITTING ELEMENT, LIGHT EMITTING DEVICE, ELECTRONIC DEVICE | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2008-05-08 | — | — | US | claimed |
| WO-2008026614-A1 | METHOD FOR SYNTHESIZING ANTHRACENE DERIVATIVE AND ANTHRACENE DERIVATIVE, LIGHT EMITTING ELEMENT, LIGHT EMITTING DEVICE, ELECTRONIC DEVICE | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2008-03-06 | — | — | WO | claimed |
| US-8748451-B2 | HDAC inhibitors and therapeutic methods of using same | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2014-06-10 | — | — | US | disclosed |
| US-20130281484-A1 | HDAC Inhibitors and Therapeutic Methods of Using Same | UNIV ILLINOIS (US) | 2013-10-24 | — | — | US | disclosed |
| US-8431538-B2 | HDAC inhibitors and therapeutic methods of using same | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2013-04-30 | — | — | US | disclosed |
| US-20120252740-A1 | HDAC INHIBITORS AND THERAPEUTIC METHODS OF USING SAME | KOZIKOWSKI ALAN (US) | 2012-10-04 | — | — | US | disclosed |
| US-8183793-B2 | Method for synthesizing anthracene derivative and anthracene derivative, light emitting element, light emitting device, electronic device | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2012-05-22 | — | — | US | disclosed |
| US-20110050118-A1 | METHOD FOR SYNTHESIZING ANTHRACENE DERIVATIVE AND ANTHRACENE DERIVATIVE, LIGHT EMITTING ELEMENT, LIGHT EMITTING DEVICE, ELECTRONIC DEVICE | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2011-03-03 | — | — | US | disclosed |
| US-20080107918-A1 | METHOD FOR SYNTHESIZING ANTHRACENE DERIVATIVE AND ANTHRACENE DERIVATIVE, LIGHT EMITTING ELEMENT, LIGHT EMITTING DEVICE, ELECTRONIC DEVICE | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2008-05-08 | — | — | US | disclosed |
| WO-2008026614-A1 | METHOD FOR SYNTHESIZING ANTHRACENE DERIVATIVE AND ANTHRACENE DERIVATIVE, LIGHT EMITTING ELEMENT, LIGHT EMITTING DEVICE, ELECTRONIC DEVICE | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2008-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120252740-A1 | HDAC INHIBITORS AND THERAPEUTIC METHODS OF USING SAME | HDAC1, HDAC9, HDAC5 | FABP4 3757/4885FABP5 2195/4885MAOA 672/4885 |
| US-20110050118-A1 | METHOD FOR SYNTHESIZING ANTHRACENE DERIVATIVE AND ANTHRACENE DERIVATIVE, LIGHT EMITTING ELEMENT, LIGHT EMITTING DEVICE, ELECTRONIC DEVICE | ALAD, CYP2C9, CYP1A1 | FABP4 3289/4885FABP5 3770/4885MAOA 445/4885 |
| US-20080107918-A1 | METHOD FOR SYNTHESIZING ANTHRACENE DERIVATIVE AND ANTHRACENE DERIVATIVE, LIGHT EMITTING ELEMENT, LIGHT EMITTING DEVICE, ELECTRONIC DEVICE | ALAD, CYP2C9, CYP1A1 | FABP4 3289/4885FABP5 3770/4885MAOA 445/4885 |
| US-20130281484-A1 | HDAC Inhibitors and Therapeutic Methods of Using Same | HDAC1, HDAC9, HDAC5 | FABP4 3757/4885FABP5 2195/4885MAOA 672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.